Serum proteomics in amnestic mild cognitive impairment

Linda IJsselstijn, Janne Papma, Lennard Dekker, W Calame, Christoph Stingl, Peter Koudstaal, Niels Prins, Peter Sillevis Smitt, Theo Luider

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)

Abstract

We have explored proteins related to mild cognitive impairment (MCI). The serum proteome of 35 amnestic MCI patients and 35 cognitively healthy persons was investigated by LC MS. We identified 108 differentially expressed peptides between MCI patients and controls, belonging to 39 proteins. Eight proteins were selected for further investigation by quantitative protein measurements using a MRM assay; apolipoprotein E, carboxypeptidase N subunit 2, complement factor B (CFAB), galectin-3 binding protein (LG3BP), lumican, serum amyloid A-4 protein (SAA4), serum amyloid P-component, and sex hormone binding globulin. Results of the quantitative protein measurements showed significantly decreased levels of carboxypeptidase N subunit 2, CFAB, LG3BP, SAA4, and serum amyloid P-component in serum from amnestic MCI patients compared with cognitive healthy controls (two-sided t-test; p < 0.05). Apolipoprotein E and lumican showed no significant difference in protein levels, sex hormone binding globulin could not be quantified since the MRM assay did not reach the required sensitivity. A model based on the three most significantly decreased proteins (CFAB, LG3BP, and SAA4) showed a sensitivity and specificity of 73 and 66%, respectively, for the initial sample set. A small external validation set yielded 77% sensitivity and 75% specificity.
Original languageUndefined/Unknown
Pages (from-to)2526-2533
Number of pages8
JournalProteomics
Volume13
Issue number16
DOIs
Publication statusPublished - 2013

Research programs

  • EMC COEUR-09
  • EMC MM-03-44-06

Cite this